"Valproic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of voltage dependent sodium channels.
| Descriptor ID |
D014635
|
| MeSH Number(s) |
D02.241.081.944.509.900 D10.251.400.895.593.900
|
| Concept/Terms |
Valproic Acid- Valproic Acid
- Propylisopropylacetic Acid
- 2-Propylpentanoic Acid
- 2 Propylpentanoic Acid
- Divalproex
Divalproex Sodium- Divalproex Sodium
- Semisodium Valproate
- Valproic Acid, Sodium Salt (2:1)
|
Below are MeSH descriptors whose meaning is more general than "Valproic Acid".
Below are MeSH descriptors whose meaning is more specific than "Valproic Acid".
This graph shows the total number of publications written about "Valproic Acid" by people in this website by year, and whether "Valproic Acid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 0 | 2 |
| 1995 | 1 | 1 | 2 |
| 1996 | 1 | 1 | 2 |
| 1997 | 1 | 1 | 2 |
| 1999 | 1 | 1 | 2 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 1 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 1 | 2 |
| 2007 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 2 | 0 | 2 |
| 2011 | 2 | 0 | 2 |
| 2012 | 1 | 1 | 2 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 3 | 3 |
| 2017 | 1 | 0 | 1 |
| 2019 | 2 | 1 | 3 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 4 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Valproic Acid" by people in Profiles.
-
Efficacy of Home Anticonvulsant Administration for Second-Line Status Epilepticus Treatment. Neurology. 2021 08 17; 97(7):e720-e727.
-
A pharmacokinetic simulation study to assess the performance of a sparse blood sampling approach to quantify early drug exposure. Clin Transl Sci. 2021 07; 14(4):1444-1451.
-
The Effect of Sample Handling on Free Valproic Acid Levels. J Appl Lab Med. 2021 04 29; 6(3):645-653.
-
Opsoclonus-Myoclonus-Ataxia Syndrome (OMAS) Associated with SARS-CoV-2 Infection: Post-Infectious Neurological Complication with Benign Prognosis. Tremor Other Hyperkinet Mov (N Y). 2021 02 10; 11:7.
-
Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. J Clin Pharmacol. 2021 06; 61(6):763-768.
-
The association of patient weight and dose of fosphenytoin, levetiracetam, and valproic acid with treatment success in status epilepticus. Epilepsia. 2020 06; 61(6):e66-e70.
-
Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet. 2020 04 11; 395(10231):1217-1224.
-
Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. N Engl J Med. 2019 11 28; 381(22):2103-2113.
-
Lessons from the Established Status Epilepticus Treatment Trial. Epilepsy Behav. 2019 12; 101(Pt B):106296.
-
Accuracy of Valproic Acid Concentration Correction Based on Serum Albumin. Neurocrit Care. 2019 04; 30(2):301-306.